Literature DB >> 33980327

Patient perspectives on the treatment burden of injectable medication for hereditary angioedema.

Cristine Radojicic1, Marc A Riedl2, Timothy J Craig3, Jessica M Best4, Jinky Rosselli4, Rebecca Hahn5, Aleena Banerji6.   

Abstract

Hereditary angioedema (HAE) is a rare, chronic disease characterized by debilitating swelling episodes in various parts of the body. Patients experience significant burdens related to the symptoms and management of HAE, which can affect their daily lives and reduce their overall quality of life. Prophylactic treatment options have expanded in the past decade to the benefit of patients; however, these therapies require scheduled injections, which can be painful, burdensome, and time consuming. We conducted an online survey of patients with HAE in the USA to better understand their experiences with available prophylactic medications and the associated treatment burdens. Our survey results suggest that most patients are satisfied with their current therapies but desire novel medications with a simpler route of administration and that, although most patients experience significant treatment-related burdens, they learn to cope with these challenges over time.

Entities:  

Mesh:

Year:  2021        PMID: 33980327     DOI: 10.2500/aap.2021.42.210025

Source DB:  PubMed          Journal:  Allergy Asthma Proc        ISSN: 1088-5412            Impact factor:   2.587


  3 in total

1.  Evaluation and management of adverse reactions to the COVID-2019 vaccines.

Authors:  Joseph A Bellanti; Russell A Settipane
Journal:  Allergy Asthma Proc       Date:  2022-01-01       Impact factor: 2.587

2.  Long-COVID and loss of smell: A post-COVID olfactory dysfunction that continues to challenge the allergist/immunologist.

Authors:  Joseph A Bellanti; Russell A Settipane
Journal:  Allergy Asthma Proc       Date:  2022-03-01       Impact factor: 2.587

3.  The allergist and IgE: The realization that allergic diseases are not all IgE mediated.

Authors:  Joseph A Bellanti; Russell A Settipane
Journal:  Allergy Asthma Proc       Date:  2021-05-01       Impact factor: 2.587

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.